FDA
-
-
-
-
-
-
-
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
-
-
-
-
-
-
-
Equillium (EQ) Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis
-
-
-
-
-
-
-
Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA
-
-
-
-
-
-
-
Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of Research & Development and Chief Medical Officer
-
-
-
-
-
-
-
After-Hours Stock Movers 10/29: (EQ) (PLT) (GOOGL) Higher; (AXGT) (COLM) (TWTR) (AAPL) Lower (more...)
-
-
-
-
-
-
-
Equillium Announces Closing of Public Offering of Common Stock
-
-
-
-
-
-
-
Equillium Announces Proposed Public Offering of Common Stock
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

